Based on research from academic schools including Princeton, Chicago and Alabama at Birmingham, the oncolytic viral therapy developer has now received more than $80m to date.
Immvira Group, a China-based cancer therapy developer founded by faculty from multiple universities, closed a $58m series B round led by private equity firm Huagai Capital yesterday.
Venture capital firm Apricot Capital also participated in the round, as did private equity firm Cowin Capital and an unnamed existing investor.
Founded in 2015, Immvira is working on cancer drugs intended to provoke the rapid spread of an oncolytic virus that will destroy malignant tumours, while remaining genetically stable for…
